Australian Clinical Labs Limited (ASX:ACL)
Australia · Delayed Price · Currency is AUD | Market Cap | 360.28M -38.5% |
| Revenue (ttm) | 737.49M +1.3% |
| Net Income | 26.31M -14.2% |
| EPS | 0.14 -8.2% |
| Shares Out | 186.67M |
| PE Ratio | 13.69 |
| Forward PE | 11.18 |
| Dividend | 0.13 (6.44%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 957,474 |
| Average Volume | 764,464 |
| Open | 1.940 |
| Previous Close | 1.945 |
| Day's Range | 1.910 - 1.940 |
| 52-Week Range | 1.915 - 3.240 |
| Beta | 0.90 |
| RSI | 33.81 |
| Earnings Date | Aug 26, 2026 |
About Australian Clinical Labs
Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ... [Read more]
Financial Performance
In fiscal year 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.
Financial StatementsNews
Australian Clinical Labs Earnings Call Transcript: H1 2026
Underlying profitability and margins improved despite a 1% revenue decline, driven by operational discipline, digitalization, and portfolio optimization. Guidance anticipates H2 market recovery, with ongoing share buybacks and cost mitigation plans for wage increases.
Australian Clinical Labs Transcript: AGM 2025
The AGM highlighted strong financial growth, strategic expansion, and operational improvements, with $44 million returned to shareholders. Despite a second strike on the Remuneration Report, all director re-elections were supported, and a new share buyback was announced.
Australian Clinical Labs Earnings Call Transcript: H2 2025
Revenue grew 6.4% to $741.3M with EBIT up 8.7% and strong cash flow, despite market softness and fee cuts. FY 2026 guidance anticipates continued margin discipline, digital billing, and operational efficiencies, with $8M EBIT uplift expected in FY 2027.
Australian Clinical Labs Earnings Call Transcript: H1 2025
Revenue grew 9.5% year-over-year to AUD 369 million, with underlying EBIT up 17% and strong cash flow. Guidance for FY25 EBIT is reaffirmed at AUD 65–73 million, with margin improvement expected in H2. Dividend of AUD 3.50 per share declared.
Australian Clinical Labs Transcript: AGM 2024
The AGM highlighted stable revenue and profit despite a sharp drop in COVID-related income, with operational improvements and a strong balance sheet supporting dividends and a share buyback. Strategic focus includes network expansion, new genetic tests, and ESG initiatives.
Australian Clinical Labs Earnings Call Transcript: H2 2024
FY24 saw stable revenue as non-COVID growth offset a sharp COVID revenue decline, with strong cash flow, margin recovery in H2, and a robust balance sheet. FY25 guidance anticipates 4–8% revenue growth, higher EBIT, and continued operational improvements.